Received Mar 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 6 | 42Y93 | IM / RA |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | TF27T | IM / LA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 3 | Y014435 | SC / LA |
patient did not have any Adverse events but was given 3 doses of DTAP-IPV (KINRIX) and MMRV (PROQUAD). Second dose was given on 10/09/2024 and third dose given on 03/11/2025. Mother to patient is worried about any reactions. Patient has not had any adverse reactions at this time. Patient was diagnosed with influenza on 03/10/2024. No severe symptoms were ongoing at the time of vaccine. patient was prescribed Ondansetron was prescribed for nausea. We have informed mom we will report the extra vaccination. There are no adverse events at this time from the vaccines given.
Influenza dx 03/10/2025
n/a
Ondansetron 4mg, Cetirizine 1mg, Fluticasone nasal suspension
N/a
n/a